INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
We are thrilled to announce a significant milestone for Invitris—a $650,000 deal plus royalties with the European market leader in technical aerosols! This achievement marks a major step forward for us, not only financially but [...]
2024 has been a transformative year for Xiretsa, filled with exciting milestones and promising opportunities. [...]
INCATE is pleased to invite researchers, clinicians, and industry experts to submit articles for an [...]
Kinzbio’s mission is to harness the power of phages—nature's precision antimicrobials—to address some of the [...]
The BamA Inhibitor project (Justus-Liebig-University Giessen) has been awarded a prestigious €180k grant through the [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
